To date, several cell cycle inhibitors are currently under investigation or are implemented in breast cancer management, including inhibitors against Wee1 [64], Aurora A [65], CDK6 [66], mutant p53 [67], and microtubule inhibitors [68]. Here, TP53 is linked to breast carcinoma.